Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 3/20 | 0.32 |
| ▸ | NOS1 | P29475 | 3/20 | 0.32 |
| ▸ | NOS2 | P35228 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.32 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19691908 | 1.00 | ALOX5 (0.55) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL19692314 | 1.00 | ALOX5 (0.55) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL1611049 | 1.00 | ALOX5 (0.55) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL1476715 | 1.00 | ALOX5 (0.55) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL2961154 | 0.94 | ALOX5 (0.50) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL2966938 | 0.94 | ALOX5 (0.50) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL18657390 | 0.88 | ALOX5 (0.65) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL29971764 | 0.88 | ALOX5 (0.65) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL18685663 | 0.88 | ALOX5 (0.65) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL9376923 | 0.87 | ALOX5 (0.43) | ALOX5ALDH1A1EPHX1TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390378-B1 | PHARMACEUTICALLY ACTIVE URIDINE ESTERS | TROMMSDORFF ARZNEIMITTEL (DE) | 2009-06-17 | — | — | EP | claimed |
| US-7396826-B2 | Pharmaceutically active uridine esters | TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2008-07-08 | — | — | US | claimed |
| US-20040121979-A1 | Pharmaceutically active uridine esters | TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2004-06-24 | — | — | US | claimed |
| US-10588962-B2 | Carbohydrate-glycolipid conjugate vaccines | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-03-17 | — | — | US | disclosed |
| US-20150238597-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-08-27 | — | — | US | disclosed |
| EP-2827899-B1 | POLYSACCHARIDE ANTIGEN-GLYCOLIPID CONJUGATE VACCINES | MAX PLANCK GES ZUR FÖRDERUNG DER WISSENSCHAFTEN E V (DE) | 2015-08-05 | — | — | EP | disclosed |
| CN-104321079-A | Carbohydrate-glycolipid conjugate vaccines | MAX PLANCK GESELLSCHAFT | 2015-01-28 | — | — | CN | disclosed |
| US-7915234-B2 | Synergistic mixture; antioxidant; cardiovascular disorders; antidiabetic agents | TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2011-03-29 | — | — | US | disclosed |
| US-7560442-B2 | Pharmaceutically active uridine esters | TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2009-07-14 | — | — | US | disclosed |
| EP-1390378-B1 | PHARMACEUTICALLY ACTIVE URIDINE ESTERS | TROMMSDORFF ARZNEIMITTEL (DE) | 2009-06-17 | — | — | EP | disclosed |
| US-7417034-B2 | Pharmaceutically active uridine esters | TROMMSDORFF GMBH & CO. KG ARZENEIMITTEL (DE) | 2008-08-26 | — | — | US | disclosed |
| US-7396826-B2 | Pharmaceutically active uridine esters | TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2008-07-08 | — | — | US | disclosed |
| EP-1666092-A2 | Drug combination comprising a fatty acid and a uridine compound. | Trommsdorff GmbH & Co.KG Arzneimittel (DE) | 2006-06-07 | — | — | EP | disclosed |
| US-20050065110-A1 | Pharmaceutically active uridine esters | TROMMSDORFF GMBH & CO., KG ARZNEIMITTEL | 2005-03-24 | — | — | US | disclosed |
| US-20050043394-A1 | Pharmaceutically active uridine esters | TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL | 2005-02-24 | — | — | US | disclosed |
| US-20050043269-A1 | Pharmaceutically active uridine esters | TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL | 2005-02-24 | — | — | US | disclosed |
| US-20040121979-A1 | Pharmaceutically active uridine esters | TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043394-A1 | Pharmaceutically active uridine esters | UMPS, UGDH, FFAR3 | ALOX5 43/4885ALDH1A1 342/4885EPHX1 879/4885 |
| US-20150238597-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | STT3B, STT3A, DDOST | ALOX5 2664/4885ALDH1A1 2693/4885EPHX1 3359/4885 |
| US-20040121979-A1 | Pharmaceutically active uridine esters | UMPS, UGDH, FFAR1 | ALOX5 49/4885ALDH1A1 142/4885EPHX1 843/4885 |
| US-20050043269-A1 | Pharmaceutically active uridine esters | UMPS, UGDH, FFAR3 | ALOX5 43/4885ALDH1A1 342/4885EPHX1 879/4885 |
| US-20050065110-A1 | Pharmaceutically active uridine esters | UMPS, UGDH, FFAR3 | ALOX5 43/4885ALDH1A1 342/4885EPHX1 879/4885 |
| US-10588962-B2 | Carbohydrate-glycolipid conjugate vaccines | STT3B, STT3A, DDOST | ALOX5 2664/4885ALDH1A1 2693/4885EPHX1 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.